Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Roche

Without Tamiflu revenues, pharma dipped.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche FY10

FY Revenues: $45.6 billion (+1%)

FY Earnings: $8.6 billion (+9%)

Comments: The company weathered the absence of Tamiflu revenues to post slight overall FY growth. Pharmaceutical sales dropped 2% to $35.6 billion. U.S. pharma sales dipped slightly to $13.5 billion, while Western Europe dropped 5% to $9.1 billion. International pharma sales (non-U.S., Western Europe or Japan) were up 8% to $8.8 billion. The company contends that U.S. healthcare reform and European austerity measures led to a $337 million hit in revenues. Avastin sales in the U.S. were flat at $3.1 bilion, while Lucentis sales rose 27% to $1.4 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters